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ABSTRACT
Canaloplasty is a relatively new non-penetrat-
ing surgery for the reduction of intraocular
pressure in patients affected by glaucoma. The
technique uses a microcatheter to perform a 360
8 cannulation of Schlemm’s canal and leaves in
place a tension suture providing an inward
distension. It aims to restore the physiological
outflow pathways of the aqueous humour and is
independent of external wound healing. Several
studies have shown that canaloplasty is effec-
tive in reducing intraocular pressure and has a
low rate of complications, especially compared
with trabeculectomy, the gold standard for
glaucoma surgery. Currently, canaloplasty is
indicated in patients with open-angle glau-
coma, having a mild to moderate disease, and
the combination with cataract phacoemulsifi-
cation may provide further intraocular pressure
reduction. This article reviews canaloplasty
indications, results and complications and
analyses its outcomes compared with tradi-
tional penetrating and non-penetrating
techniques.
Keywords: Canaloplasty; Deep sclerectomy; Gl-
aucoma; Ophthalmology; Phaco-canaloplasty;
Trabeculectomy; Viscocanalostomy
INTRODUCTION
Glaucoma is one of the leading causes of
blindness worldwide [1]. Primary open-angle
glaucoma (POAG), the most common type of
glaucoma in white populations [2], has a typi-
cally chronic course, characterized by progres-
sive damage to the optic disc and visual field
deterioration [3, 4]. Although several risk factors
for glaucoma have been investigated [5–9],
reduction of intraocular pressure (IOP) remains
the mainstay of glaucoma treatment as studies
have clearly shown a positive effect of IOP
reduction on both glaucoma development and
progression [10–16].
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The first approach in reducing IOP generally
consists of topical medications. However, when
target IOP is not achievable or progression is
detected in spite of maximum tolerated medical
therapy, surgery is advisable [17, 18].
Trabeculectomy (TRAB) is actually the gold-s-
tandard procedure for glaucoma surgery. How-
ever, it is plagued by a major rate of intra- and
postoperative complications, such as choroidal
haemorrhage [19, 20], cataract development
[21], hypotony [22, 23], bleb leakage [24, 25]
and infections [26]. These complications are
largely due to the creation of a patent commu-
nication between the anterior chamber and sub-
conjunctival space as a full thickness sclero-
tomy is performed during the procedure (i.e.,
penetrating surgery). To reduce these compli-
cations, non-penetrating surgeries have been
proposed [27]. In these procedures there is no
direct communication between the anterior
chamber and extraocular spaces. For this reason
they are considered safer than TRAB at the cost
of lower hypotensive efficacy [27, 28]. Deep
sclerectomy (DS), a non-penetrating procedure,
creates a trabeculo-descemetic window through
which aqueous humour (AH) slowly leaks from
the anterior chamber [29]. Viscocanalostomy
(VC), another non-penetrating procedure, aims
to restore the physiological AH filtration path-
way, expanding Schlemm’s canal by means of
the viscoelastic substance [30].
Canaloplasty (CP) is a relatively new non-
penetrating technique and can be considered a
technical amelioration of VC. Described in 2005
by Kearney et al., it uses a breakthrough
microcatheter technology to restore the physi-
ological AH outflow system [31]. Clinical stud-
ies have shown that CP, performed alone or in
conjunction with cataract extraction, reduces
IOP significantly and in the long term, with an
excellent safety profile. The objective of this
review is to describe the CP surgical technique,
its indications and the results in terms of the
hypotensive efficacy and safety profile. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
PATIENT SELECTION
CP is mainly indicated in patients affected by
POAG when IOP is not satisfactorily controlled
with medical therapy or medications are not
tolerated [32, 33]. Patients affected by pigmen-
tary glaucoma or pseudoexfoliative glaucoma
are candidates for this surgery as well as long as
the irido-corneal angle is open and easily
accessible. A few reports have described the use
of CP in patients affected by juvenile glaucoma
[34] and in some phenotypes of secondary
glaucoma, such as steroid-induced glaucoma
[35] or glaucoma secondary to uveitis [36]. An
exploratory indication for CP may be in patients
with a previous failed TRAB when gonioscopic
examination reveals an intact Schlemm’s canal
[37, 38] or even in case of a disrupted canal wall
[39, 40] (Fig. 1).
Careful evaluation of patient’s clinical char-
acteristics is always mandatory when selecting a
surgical procedure. Patients with moderate/high
IOP and without advanced visual field and/or
optic disc damage probably benefit more from
CP as extremely low IOPs are not required. The
absence of a filtration bleb and its non-pene-
trating nature make CP particularly attractive
for patients at high risk of infections or chor-
oidal bleeding, with enhanced wound healing
or with complications from a previous TRAB in
the contralateral eye [41]. Finally, young
Fig. 1 Gonioscopic image of a canaloplasty performed
after trabeculectomy: Prolene suture in place
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patients with moderate IOP and used to contact
lens wearing may benefit from this bleb-less
procedure.
Contraindications are angle-closure glau-
coma, post-traumatic glaucoma with angle
recession and almost all the secondary glauco-
mas (neovascular glaucoma, aphakic glaucoma,
etc.) with the exceptions already described [42].
Angle closure is a contraindication for canalo-
plasty, mainly for two reasons: (1) persistent
irido-trabecular contact results in a progressive
process of Schlemm’s canal endothelial damage
and Schlemm’s canal occlusion, making the
microcatheter passage not easily achievable
[43]; (2) irido-trabecular contact and peripheral
anterior synechiae block AH outflow anteriorly
to Schlemm’s canal, damaging the trabecular
meshwork and increasing resistance at this level
[43]. Patients with narrow angles or plateau iris
may benefit from this technique when per-
formed in combination with cataract extraction
as tensioning the suture may result in further
narrowing of the angle.
SURGICAL PROCEDURE
Sub-conjunctival or peri-bulbar anaesthesia is
generally performed, but general anaesthesia
could sometimes be preferred in young patients
and in myopic eyes. A 4-0 suture under the
superior rectus muscle insertion or a corneal
bridle suture may be placed to better expose the
surgical field and rotate the eye inferiorly.
Conjunctiva and Tenon’s capsule are gently
dissected, creating a fornix-based flap, usually at
12 o’clock position. Differently from TRAB, it is
advisable to avoid cauterization, preserving
episcleral vessels. Topical vasoconstrictor agents
may be used. A superficial scleral flap is dis-
sected, carrying forward the incision up to clear
cornea (Fig. 2a). The shape of the superficial flap
may vary, according to the surgeon’s experience
and preferences (generally a parabolic flap is
created). However, flap thickness should be
approximately fixed to one third of the total
scleral thickness (200–250 lm). A smaller and
deeper scleral flap is then sculpted just above
the choroidal plane and extended forward to
slice the scleral spur (Fig. 2b). In this way,
Schlemm’s canal is opened and a trabeculo-de-
scemetic window is created. A gentle pressure at
the level of the Schwalbe line, using a cellulose
sponge, may help further extend the trabeculo-
descemetic window, encouraging AH leaks. At
this point, the internal wall of Schlemm’s canal
should be removed with micro-surgical forceps.
The deep flap is then dissected away, and the
two ostia of Schlemm’s canal are exposed
(Fig. 2c).
Repeated visco-dilatation of the ostia with a
microcannula is performed (Fig. 2d). The
microcatheter (iTrack 250, Ellex iScience, Inc.,
Freemont, CA, USA) has a 250 lm diameter and
an embedded optical fibre connected to a laser
flickering red light source for easy identification
of the distal tip through the sclera. The micro-
catheter is inserted into Schlemm’s canal
through the exposed ostia and advanced
throughout the 360 (Fig. 2e). When the distal
tip of the catheter emerges at the opposite site, a
10-0 Prolene suture is tied to the tip, and the
microcatheter is withdrawn, injecting approxi-
mately 0.5 ll of viscoelastic material every 2 h
(Fig. 2f). A high-weight molecular viscoelastic
agent is preferred during this phase. Viscodila-
tion of Schlemm’s canal is an essential part of
the procedure as it breaks adhesion inside the
canal, stretches the trabecular plates by means
of micro-perforations into the inner wall of the
trabecular meshwork and separates herniations
of the inner wall of the trabecular meshwork
into the outer wall collector channels. The tip is
then extracted from Schlemm’s canal at the
initial surgical site, and the suture is knotted
under tension to obtain an inward distension of
the trabecular meshwork (Fig. 2g). High-resolu-
tion UBM may be used in this phase, if avail-
able, to evaluate the tension of the suture and
the dilatation of Schlemm’s canal. Finally, the
superficial scleral flap is tightly closed with
several Vicryl or nylon stitches to ensure a
watertight closure, and the conjunctival flap is
sutured (Fig. 2h). Postoperative treatment con-
sists of antibiotic drops for a week and local
steroids or nonsteroidal anti-inflammatory
drops for a period of 4–6 weeks, according to the
surgeon’s habits and patient’s course.
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ADVERSE EVENTS
CP is a safe procedure, and complications, both
intra- and postoperative, are generally mild
(Table 1) [32, 33]. While intraoperative compli-
cations decrease with the surgeon’s experience
and after a long learning curve, postoperative
complications are usually self-resolving, requir-
ing no direct intervention.
Intraoperative Complications
A relatively frequent intraoperative complica-
tion of CP is the rupture of the trabeculo-de-
scemetic membrane, especially at the beginning
of the learning curve. From previous studies,
rupture of the trabeculo-descemetic window has
been reported in 1.8–8.5% of cases [34, 44, 45].
Micro-ruptures are generally not a problem, and
the procedure may be completed as usual [34].
However, if a macro-perforation or iris prolapse
is evident, it is advisable to convert the proce-
dure to a penetrating surgery (i.e., TRAB).
Schlemm’s canal cannulation cannot be
completed in approximately 7.3–26% of cases
because of anatomical anomalies of Schlemm’s
canal, trabecular meshwork scars or other rea-
sons, but this percentage tends to decrease with
experience [34, 44–46]. The microcatheter may
stick at the entrance of a large collector chan-
nel, resisting the surgeon’s attempts of
advancement. In these cases it may be useful to
slightly push over the distal tip of the catheter
at the level of the limbus. If this is not useful,
the catheter should be retracted, and the can-
nulation should be tried through the ostium
Fig. 2 Canaloplasty surgical technique. a Dissection of the
superficial scleral flap; b creation of a deep scleral flap;
c cutting of the deep scleral flap and exposure of
Schlemm’s canal ostia; d viscodilation of Schlemm’s canal
ostia with a microcannula; e advancement of the micro-
catheter through Schlemm’s canal; f knotting of the 10-0
Prolene suture on the microcatheter tip; g tensioning of
the Prolene suture; h watertight suture of the scleral flap
Table 1 Frequency of canaloplasty-related adverse events
Adverse event Frequency
(%)
Intraoperative complications
Rupture of trabeculo-descemetic
membrane
1.8–8.5
Schlemm’s canal cannulation not
possible
7.3–26
Descemet’s membrane detachment 1.6–9.1
Postoperative complications
Hyphaema/microhyphaema 6.1–85.2
IOP spike 1.6–30
YAG-laser goniopuncture 0–22
Cataract formation 0–8.4
Suture extrusion 0–6.7
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opposite from Schlemm’s canal. Creation of a
false path and penetration of the microcatheter
into the anterior chamber are exceptional
intraoperative complications, and their inci-
dence decreased with the surgeon’s experience
[41].
Descemet’s membrane detachment is a rare
but potentially vision-threatening complication
[47, 48]. Its frequency has been reported
between 1.6% and 9.1% [44–46, 49]; however
one case of bilateral Descemet’s membrane
detachment has been reported [34]. Descemet’s
membrane detachment happens when there is a
strong adhesion between the inner and outer
walls of Schlemm’s canal, exceeding the resis-
tance of the junction between Descemet’s
membrane and Schwalbe’s line. Forcing vis-
coelastic material in these cases may cause a
Descemet’s membrane detachment. Descemet’s
membrane detachment is usually limited in size
(1–2 mm) and resolves spontaneously. Rarely, it
may extend until the visual axis, requiring
additional intervention [44, 50].
Postoperative Complications
Microhyphaema is the most common postop-
erative complication of CP and is generally
observable the 1st day after surgery. It has been
reported in 6.1–85.2% of cases [34, 45, 46, 51].
Bleeding is considered a positive prognostic
factor as it is due to blood reflux from the col-
lector channels, indicating a patent and func-
tioning outflow pathway [51]. Hyphaema is
generally mild and resolves spontaneously in a
few days or weeks from surgery.
IOP spikes in the days immediately following
surgery have been reported in up to 30% of
cases [34, 41, 44–46, 49, 52–54]. IOP spikes are
probably due to remnants of viscoelastic mate-
rial in Schlemm’s canal, preventing AH outflow.
IOP generally stabilizes 24–48 h after surgery,
without the need for further intervention, when
viscoelastic material has been completely reab-
sorbed. However, if IOP does not decrease
spontaneously in 4–6 weeks, it is advisable to
perform a Nd:YAG-laser goniopuncture.
Laser goniopuncture creates a full-thickness
opening in the trabeculo-descemetic window,
converting the procedure in a penetrating sur-
gery. In published studies, goniopuncture has
been performed in up to 22% of patients in the
1st year from surgery with good IOP control
[32, 34, 44–47].
A transient decrease in visual acuity is a
common finding during the first 2 weeks after
surgery due to an induced with-the-rule
astigmatism.
Cataract formation, a troubling complica-
tion especially in young subjects, has been
described in 0–8.4% of patients who had previ-
ously undergone CP [32, 45, 46]. Compared
with TRAB, for which cataract formation has
been reported in approximately 50% of cases
[55–57], this percentage is far less. The effect of
cataract extraction on eyes that have already
undergone CP actually remains unknown. In a
retrospective subgroup analysis of a larger sam-
ple of patients that previously underwent CP,
Tetz et al. found a non-significant IOP reduc-
tion in 19 eyes after cataract extraction [52].
However, 4 of the 19 eyes (21.2%) showed an
increase in IOP C 2 mmHg at the first subse-
quent study visit.
Complications related to the Prolene suture
are rare. Suture extrusion has been described in
0–6.7% of cases [32, 47, 54], with no serious
consequences. Uniformly distributed tension
around the suture may decrease the risk of
damage to the inner wall of Schlemm’s canal
and increase the strength of the trabecular
meshwork related to suture tension.
A late IOP rise can be observed even years
after a successful CP. In these cases, an ab
interno stripping of the Prolene suture [58, 59]
or a TRAB [60] should be performed.
RESULTS
Several studies have confirmed the short- and
long-term hypotensive efficacy of CP. A multi-
centre study carried out at 15 clinical sites in US
and Germany enrolled 157 patients affected by
open-angle glaucoma (OAG), many of them on
maximum tolerated medical therapy [46–48].
CP alone was performed on 122 patients
(77.1%), while CP combined with cataract sur-
gery (phaco-canaloplasty, PCP) was performed
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on 36 patients (22.9%). Follow-up examinations
were scheduled at 1 day, 1 week and 1, 3, 6, 12,
18, 24, 30 and 36 months after surgery. Primary
outcomes included IOP and glaucoma medica-
tions. At the 3-year follow-up visit, mean IOP
for the entire group was 15.2 ± 3.5 mmHg, and
mean number of glaucoma medications was
0.8 ± 0.9 compared with a baseline IOP of
23.8 ± 5.2 mmHg and mean number of glau-
coma medications of 1.5 ± 1.0. When only
patients with successful suture positioning were
evaluated (133 eyes, 84.7%), IOP was found to
be reduced by 34% and 42.1% in the CP and
PCP group, respectively. IOP difference between
the CP and PCP group was significant in all
study visits (p = 0.095). High-resolution UBM
images of the anterior segment were obtained
from study eyes pre-, intra- and postoperatively.
Suture-tensioning significantly influenced the
IOP decrease at 24 months: patients with no
evident tension at UBM examination had a 20%
decrease in IOP from baseline and a 60%
reduction in medication use; patients with an
observable tension had a 31% reduction in IOP
and a 75% reduction in medication use [47].
A sub-analysis of the data from the previous
study aimed to investigate the hypotensive
efficacy of CP according to the surgical treat-
ment received in three different groups of
patients: group 1, CP in phakic eyes; group 2,
CP in pseudophakic eyes; group 3, eyes having
PCP [52]. At 3 years, IOP outcomes of group 1
(phakic eyes) and group 2 (pseudophakic eyes)
were similar (mean IOP: 15.5 ± 3.5 and
15.6 ± 3.5 mmHg, p = 0.976, respectively).
Group 3 (PCP eyes) had significantly lower IOP
values (mean IOP: 13.6 ± 3.6 mmHg) than
group 1 (p = 0.044), but similar to group 2
(p = 0.121). Mean number of medications at the
3-year follow-up visit was significantly lower in
group 3 (0.3 ± 0.5) compared with group 1
(0.9 ± 1.0, p\ 0.001) and group 2 (1.1 ± 0.8,
p\0.001).
A European prospective multicentre study
with a similar design was performed in Ger-
many on 109 eyes of patients affected by OAG
[45]. Inclusion criteria were a preoperative IOP
of at least 16 mmHg and an anamnestic IOP of
at least 21 mmHg, with or without medical
treatment. Ninety-three eyes underwent CP
(85.3%) and 16 eyes underwent PCP (14.7%).
Successful positioning of the tension suture was
achieved in 98 eyes (85.3%). Mean baseline IOP
was 23.0 ± 4.3 and 24.3 ± 6.0 mmHg in the CP
and in the PCP group, respectively. At the 3-year
follow-up visit, IOP was reduced by 34.3%
(mean IOP: 15.1 ± 3.1 mmHg) in eyes that
underwent CP and by 43.2% (mean IOP:
13.8 ± 3.2 mmHg) in eyes that underwent PCP
(p = 0.22). Although IOP was constantly lower
in the PCP group at all study visits, no signifi-
cant difference between the two groups was
reported.
Grieshaber et al. performed CP on 60 black
African patients affected by advanced POAG,
with a mean baseline IOP of
45.01 ± 12.1 mmHg [41]. CP was the first sur-
gery for almost all the patients (59/60). The
complete success (i.e., without medications)
rate of an IOP\21, 18 and 16 mmHg was 81,
67.8 and 47.2% at 36 months, respectively.
Surgery outcome was not influenced by preop-
erative IOP, age or genre. The same author
reported the results of a prospective study on 32
white OAG patients having CP as primary sur-
gery [49]. Mean IOP was reduced from
27.3 ± 5.6 mmHg at baseline to
12.8 ± 1.5 mmHg at 12 months. When success
was defined as an IOP B 21, 18 and 16 mmHg,
complete success was achieved in 93.8, 84.4 and
74.9% of eyes at 12 months, respectively.
Nd:YAG-laser goniopuncture was performed in
six eyes (18.1%) when IOP exceeded the target
of 16 mmHg. Partial Descemet membrane
detachment occurred in two eyes during the
surgery and in four eyes the microcatheter
entered the suprachoroidal space. Both of these
complications had no serious consequences.
In the study reported by Brusini, 256 patients
affected by OAG and on maximum tolerated
medical therapy underwent CP, with a mean
postoperative follow-up of 20.3 ± 10.6 months
[34]. The full procedure could not be performed
in 42 eyes (16.4%) due to either a large perfo-
ration of the trabeculo-descemetic membrane
with iris prolapse (2 eyes) or the impossibility of
cannulating the full 360 of Schlemm’s canal
(40 eyes). In these cases, anatomical obstacles
and/or other intraoperative complications, such
as the misdirection of the microcatheter into
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the anterior chamber, were the more frequent
causes for aborting the procedure. Therefore,
statistical analysis was performed on 214 eyes.
Complete success criteria were defined as a
postoperative IOP B 21, 18 or 16 mmHg. Qual-
ified success criteria were defined in the same
manner; however medical therapy was allowed.
Mean preoperative IOP was 29.4 ± 7.9 mmHg.
Complete success rates at 3-year follow-up were
44.8, 31.0 and 24.1% for the 21, 18 and
16 mmHg criterion, respectively. Qualified suc-
cess rates at 3-year follow-up were 86.2, 58.6
and 37.9%, for the 21, 18 and 16 mmHg crite-
rion, respectively. Number of glaucoma medi-
cations was 3.3 ± 0.9 before surgery and
decreased to 1.3 ± 1.5 at 36 months.
The same author reported a multicentre
interventional study in which 218 eyes from
197 OAG patients on maximum tolerated
medical therapy underwent CP [44]. The full
procedure could not be performed in 20 eyes
(9.2%) and consequently the statistical analysis
was performed on 198 eyes from 178 patients.
Criteria of complete and qualified success were
defined as in the previous study. At 2-year fol-
low-up visit, qualified success was obtained in
82 (92.1%), 75 (84.3%) and 61 (68.5%) eyes for
the 21, 18 and 16 mmHg criterion, respectively.
Complete success was achieved in 63 (70.8%),
60 (67.4%) and 53 (59.5%) eyes for the same
criteria of success. Laser goniopuncture was
performed in 18 eyes (9.9%, 2–12 months after
surgery). Number of glaucoma medications
decreased from 3.2 ± 0.9 before surgery to
1.1. ± 1.3 at 2-year visit.
In a retrospective study by Khaimi et al.
3-year results of CP performed on 277 OAG eyes
were reported [61]. One hundred fifty eyes had
CP, while 127 eyes had PCP. Mean baseline IOP
for the entire group, the CP group and PCP
group was 19.7 ± 6.7, 21.1 ± 7.2 and
18.1 ± 5.6 mmHg, respectively. After
36 months, mean IOP decreased to
15.2 ± 4.3 mmHg in the entire group,
15.0 ± 4.6 mmHg in the CP group and
15.4 ± 4.0 mmHg in the PCP group (p\0.01
for all the comparisons). When a success crite-
rion of an IOP\15 mmHg and a reduc-
tion[ 25% from baseline was considered,
40.5% and 43.2% of eyes that had undergone
CP achieved the complete and qualified success
at 36 months, respectively. However, only 7.4%
and 18.5% of eyes that had undergone PCP
satisfied the same success criteria.
COMPARISON
WITH TRABECULECTOMY
Several studies compared the efficacy and safety
of CP with TRAB, the gold-standard procedure
for glaucoma surgery [54, 62–66]. Generally,
TRAB was more effective than CP in reducing
IOP at the cost of a major rate of adverse events.
In a retrospective study, Ayyala et al. com-
pared operative outcomes of CP and TRAB after
a 12-month follow-up [62]. CP and TRAB plus
mitomycin-C (MMC) were performed on 33 and
46 POAG eyes, respectively. Mean percentage
decrease in IOP from preoperative values at
12 months was 32 ± 22% in the CP group and
43 ± 28% in the TRAB group (p = 0.072). When
the success criterion was defined as an
IOP\18 mmHg but [ 4 mmHg, success was
achieved in 87.9% (29/33) and 95.7% (44/46) of
eyes in the CP and TRAB group, respectively.
However, the difference was not significant
(p = 0.23). Regarding complications, only
hyphaema was more frequent in the CP than in
the TRAB group (21% vs. 2% of eyes, respec-
tively, p\ 0.01). Choroidal effusion (8 eyes),
suprachoroidal haemorrhage (1 eye) and
hypotony maculopathy (2 eyes) were reported
only in the TRAB group.
Bruggemann et al. compared the efficacy and
safety of CP in one eye versus TRAB plus MMC
in the contralateral eye in patients affected by
OAG [63]. Thirty patients were included in this
study. Mean preoperative IOP was 26.73 ± 6.4
and 26.3 ± 10.9 mmHg in eyes having CP and
TRAB, respectively. Three eyes in the CP group
(20%) had a combined procedure of CP and
cataract extraction. Mean IOP reduction at
12-month follow-up was 14.6 ± 4.5
(50.3% ± 10.5%) and 15.2 ± 11.2 mmHg
(53.4% ± 20.1%) in the CP and TRAB eyes,
respectively. The difference between the two
groups was not significant (p = 0.87). In the CP
group, a shallow hyphaema\1.5 mm occurred
in four eyes (26.7%), a peripheral Descemet’s
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membrane detachment in one eye (6.7%) and a
shallow anterior chamber in one eye (6.7%), the
1st day after surgery, requiring injection of vis-
coelastic material. In the TRAB group, two eyes
(13.3%) had a shallow anterior chamber
immediately after surgery, requiring viscoelastic
injection (one eye required four repeated injec-
tions), five eyes (33.3%) had intermittent chor-
oidal detachment and one eye (6.7%) had
hyphaema. Before the end of the study, two
eyes (13.3%) in the TRAB group required catar-
act extraction. Laser goniopuncture was per-
formed only in one eye in the CP group.
Matlach et al. performed the first prospective
randomized clinical trial comparing TRAB and
CP [54]. The TVC (TRAB versus CP) study
enrolled 62 patients affected by OAG, random-
ized to TRAB (n = 32) or CP (n = 30). Patients
were followed up prospectively for 2 years. Cri-
teria of success were defined as an
IOP B 18 mmHg or an IOP reduction C 20%
from baseline (criterion 1) and as an
IOP B 21 mmHg (criterion 2). Median baseline
IOP was 20.0 mmHg in the TRAB group and
22.0 mmHg in the CP group (p = 0.06). When
complete success (without medications) criteria
were considered, the treatments of 23 (74.2%)
and 9 (39.1%) patients were classified as suc-
cessful according to criterion 1, and treatments
of 21 (67.7%) and 9 (39.1%) patients were
classified as successful according with criterion
2 in the TRAB and CP group, respectively, at
2 years. The difference between groups was sig-
nificant for both the 18 and 21 mmHg criterion
(p = 0.01 for criterion 1 and p = 0.004 for crite-
rion 2). When qualified success (with or without
medications) criteria were considered, treat-
ments of 90.3% and 82.6% of patients were
classified as successful according to criterion 1
and 96.8% and 82.6% were classified as suc-
cessful according to criterion 2 in the TRAB and
CP group, respectively. The difference between
groups was significant only for criterion 2
(p = 0.01). Surgery-related adverse effects were
more frequent in the TRAB group. Common
complications of TRAB were transient hypotony
(37.5%), hypotony-related choroidal detach-
ment (12.5%), shallow anterior chamber (6.2%),
elevated IOP (25.0%) and corneal erosion,
probably due to 5-fluorouracil (5FU) injections.
In the CP group, common complications were
elevated postoperative IOP ([25 mmHg) in
30% of patients and hyphaema in 23.3% of
patients, which resolved spontaneously in the
1st postoperative week. More postoperative
interventions were reported in the TRAB group
as bleb management included 5FU injections,
laser suturolysis and bleb needling.
Difference in hypotensive efficacy and safety
between TRAB and CP has been evaluated in
meta-analysis studies [27, 66]. In the meta-
analysis by Lin et al. on 215 patients from 4
previously published studies, mean difference
in IOP between TRAB and CP at 12 months was
2.33 mmHg (95% CI: 0.66; 4.0, p\0.01) [66].
However, when a success criterion of
IOP\18 mmHg was considered, no significant
difference was found between TRAB and CP for
both the complete (without medications,
p = 0.19) and qualified (with or without medi-
cations, p = 0.39) successes. CP had a lower
incidence of choroidal detachment than TRAB
(OR: 0.12, 95% CI: 0.03; 0.48, p\0.01) and a
higher incidence of hyphaema (OR: 8.80, 95%
CI: 2.25; 34.51, p\0.01). Fewer patients in the
CP group than in the TRAB group had some
other adverse events.
According to the meta-analysis by Zhang
et al., TRAB was more effective than CP in
reducing IOP by 3.65 mmHg (95% CI - 6.42;
- 0.88, p = 0.01) at 12 months from surgery
[65]. However, no significant difference
between CP and TRAB was found regarding the
reduction in medication number (p = 0.20).
Comparing PCP with phaco-TRAB, phaco-TRAB
showed a mean advantage of 4.02 mmHg over
CP (95% CI - 7.62; - 0.42, p = 0.03) at 1 year.
Difference in medication number was still not
significant (p = 0.32). However, only two stud-
ies were included in this analysis. Hyphaema
was more frequent in CP than TRAB (OR: 9.24,
95% CI: 3.09; 27.60, p\ 0.01). Descemet’s
membrane detachment was observed only in
CP, with a reported incidence of approximately
3%. Hypotony (OR: 0.32, 95% CI 0.13; 0.80,
p = 0.01) and choroidal effusion (OR: 0.25; 95%
CI 0.06; 097, p = 0.04) were complications with
significantly fewer incidents in the CP group.
Quaranta et al. evaluated the increase in IOP
during the postural change from sitting to
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supine position in a population of 52 POAG
patients previously having successful TRAB
(n = 26) or CP (n = 26) in one eye [64]. In each
patient, sitting IOP measurement with a Gold-
mann applanation tonometer was followed by
supine Perkins tonometry after 30 min of rest in
the supine position. Mean postoperative sitting
IOP was 10.2 ± 2.3 and 15.3 ± 2.2 mmHg in
the TRAB and CP eyes, respectively (p\0.01).
In both cohorts supine IOP was significantly
higher than sitting IOP (p\ 0.01). In the CP
eyes, the relative increase in IOP going from
sitting to supine was 28.4% (absolute difference:
4.3 ± 1.9 mmHg), whereas in the TRAB eyes it
was 18.1% (absolute difference:
1.7 ± 0.9 mmHg). The increase in IOP from the
sitting to supine position was significantly
greater in the CP group (p\0.01) and similar to
the one obtained in the contralateral non-op-
erated eye (29.8% in CP patients and 30% in
TRAB patients). The authors concluded that the
increase in IOP due to postural change is virtu-
ally not influenced by CP, probably because
Schlemm’s canal surgery, differently from
TRAB, aims to restore the physiological AH
outflow pathways.
COMPARISON WITH OTHER NON-
PENETRATING SURGERIES
The main difference between CP and VC is that
CP aims to re-open the entire Schlemm canal
and not only a part of it [32]. Moreover, the
positioning of a tensioning suture inside Sch-
lemm’s canal potentially reduces the risk of
Schlemm’s canal re-collapse in the long term. In
a study by Koerber et al. the hypotensive effi-
cacy of CP in one eye was compared with VC in
the contralateral eye in a population of 15
patients affected by OAG [67]. Baseline mean
IOP was 26.5 ± 2.7 and 24.3 ± 2.8 mmHg in
the CP and VC eyes, respectively. CP achieved a
significantly greater decrease in IOP
(* 12 mmHg) than VC (* 8 mmHg) at the
18-month follow-up visit (p = 0.02). However,
the final absolute IOP was not significantly dif-
ferent between CP and VC (14.5 ± 2.6 and
16.1 ± 3.9 mmHg for CP and VC, respectively,
p = 0.24). When the success criterion was
defined as an IOP reduction C 30% and an
absolute value\18 mmHg, 86.7% and 60.0%
of eyes in the CP group and 50% and 35.7% of
eyes in the VC group achieved a qualified (with
medications) and a complete (without medica-
tions) success, respectively.
Hypotensive efficacy and safety of CP and
VC in POAG patients on maximum medical
therapy were recently evaluated in a short-term
follow-up study by Wagdy et al. [68]. In this
study, 30 patients had CP with a baseline mean
IOP of 27.2 ± 1.9 and 30 patients had VC with a
baseline mean IOP of 26.4 ± 2.95 mmHg. At
6 months from surgery, IOP was 15.6 ± 1.2 and
16.9 ± 1.32 mmHg in the CP and VC group,
respectively. Fewer complications were gener-
ally reported for the CP than for the VC group.
However, no direct comparison between the
two groups was performed, so no clear conclu-
sions can be drawn about these results.
PCP and phaco-DS were compared with a
paper by Rekas et al. [69]. In this study, 29 eyes
had PCP and 30 eyes had phaco-DS with a
Healaflow implant for uncontrolled POAG.
Mean IOP decreased from 19.0 ± 6.9 to
12.6 ± 2.7 mmHg and from 19.1 ± 5.8 to
14.3 ± 3.5 mmHg at 12 months in the PCP and
phaco-DS group, respectively. No difference in
IOP was found between the two groups
(p = 0.107) at 12 months. Mean number of
hypotensive medications was reduced from
2.64 ± 0.68 to 0.27 ± 0.67 in the PCP group
and from 2.89 ± 0.94 to 0.55 ± 0.94 in the
phaco-DS group. Again, no difference was
found between the two groups (p = 0.304). PCP
showed a higher incidence of postoperative
hyphaema (58.6% of eyes) and one case (3.4%)
of Descemet’s membrane detachment. Both the
hyphaema and Descemet’s membrane detach-
ment resolved spontaneously with no conse-
quences. On average, 3.7 injections of 5FU per
patient (range 1–10) were performed in the
phaco-DS group, and 17 (56.6%) eyes had
goniopuncture.
In another study, the same group of authors
reported on the results of a 24-month compar-
ison between PCP and phaco-DS. In this study
37 eyes were randomized to receive PCP and 38
eyes to receive phaco-DS [70]. Quality of life
(QoL) was evaluated by the means of the
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National Eye Institute Visual Function Ques-
tionnaire-25 items (NEI-VFQ-25). IOP decreased
from 19.4 ± 5.8 mmHg preoperatively to
13.8 ± 3.3 mmHg at 24 months and from
19.7 ± 5.4 mmHg preoperatively to
15.1 ± 2.9 mmHg at 24 months in the PCP and
phaco-DS group, respectively. Starting from
6 months after surgery, IOP was significantly
lower in the PCP group, and the difference
remained significant until the 24-month visit
(p = 0.04). After surgery, the NEI VFQ-25 mean
composite score for PCP patients was
78.04 ± 24.36 points and for phaco-DS patients
was 74.29 ± 24.45 points (p = 0.136). At
24 months, 68% of PCP eyes and 43% of phaco-
DS eyes did not require any glaucoma medica-
tion, although the difference in mean medica-
tion number between the two groups was not
significant (0.5 ± 0.9 and 1.1 ± 1.2, p = 0.058).
Hyphaema was observed in 17 PCP eyes (46%)
and in all but one case resolved spontaneously.
One case of peripheral Descemet’s membrane
detachment was reported in the PCP group. In
the phaco-DS group, 36 eyes (94.7%) received
5FU injections, 13 eyes (34%) suture-lysis and 9
eyes (24%) bleb needling. Nd:YAG-laser
goniopuncture was performed in 14 (36.6%)
phaco-DS eyes and in 8 (22%) PCP eyes.
CONCLUSIONS
CP is an effective and safe procedure to lower
IOP in patients affected by OAG. Its advantages
include no bleb formation, an easier follow-up
and better safety profile compared with TRAB,
which currently is the gold standard in glau-
coma surgery. A target IOP around 15 mmHg is
easily achievable with this procedure, with or
without the use of topical medications, and the
association with cataract extraction may further
reduce IOP. For these reasons, CP is mainly
indicated in OAG patients who do not require a
particularly low-target IOP regardless of the
preoperative IOP values or in patients with sig-
nificant risk factors for intra- or postoperative
complications from TRAB. Disadvantages of this
technique are extensive conjunctival and scleral
manipulations that strongly limit the possibility
of performing a subsequent TRAB, the long
learning curve, the need for specific and
expensive instrumentation and the unfeasibil-
ity in some patients due to anatomical limita-
tions, angle closure or secondary glaucomas.
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